PKCd Inhibitors, Great Acquisition in Drug DiscoveryThe Acquisition of Sapientia today is a great move by Briacell. Bringing on-board some seriously decorated scientists and researchers. The PKCd Inhibitors together with current development of BriaDX, carries some major potential for advancing Briacell in the oncology drug development sector. I feel there could be some big investment coming from this merger. Combining the two company's is a major win for current investors. jmo.